Recent preclinical studies have provided compelling evidence that pharmacological targeting of DHODH synergizes with GPX4 inhibitors, immune checkpoint blockade, or standard chemotherapeutics to enhance ferroptotic cell death and restrict tumor progression [18,19]. This evidence concerns the gene GPX4 and neoplasm.